Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune d...
The partnership combines Secarna’s OligoCreator® technology with Vect-Horus’ VECTrans® platform to enable system...
Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of...
Synfini, Inc., a trailblazer in AI-driven chemistry automation, today announced a $8.9 million expansion of its round, led by JSL Health Capital and supp...
PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery techn...
The submission is based on results from the Phase 3 AMPLITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisone or predn...
Abinopharm, Inc., an innovative nutritional and biopharmaceutical company based in Shelton, Connecticut, USA, is pleased to announce that its partner, EG...
Data presented today at the ESHRE congress builds evidence for conventional-based Follicular Stimulating Hormone (FSH) dosing for Rekovelle® (fol...
Asahi Kasei Pharma has started trial drug administration in a Phase III study of ART-123 in Japan (generic name: thrombomodulin alfa; marketed as Recomod...
MaaT Pharma and Clinigen signed exclusive long-term licensing and distribution agreement and commercial supply agreement for Xervyteg® (MaaT013),...
-Modella AI, a leader in artificial intelligence for life sciences, announced a multi-year agreement with AstraZeneca. Under the agreement, Modella...
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Adva...
Artelo Biosciences, Inc. a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people liv...
HUTCHMED (China) Limited announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolitinib) and TAGRISS...
© 2025 Biopharma Boardroom. All Rights Reserved.
